While conventional in vitro and in vivo assays have long served as the foundation of adventitious virus testing, evolving modalities, complex raw materials, and emerging viral risks are challenging the limits of traditional detection methods.
In this webinar, speaker Christine Mitchell examines the current viral safety testing landscape and explores how next-generation sequencing (NGS) can enhance detection breadth, sensitivity, and risk mitigation strategies. Learn how advanced, GMP-ready genomic approaches such as AgentSCREEN™ complement conventional assays to help identify viral contaminants that may otherwise go undetected.
Watch the on-demand recording below to gain practical insights into strengthening your viral safety program with modern, science-driven solutions.
Key takeaways
- Understand the limitations of conventional viral detection methods and where detection gaps may exist.
- Explore how NGS expands detection capability beyond predefined or assay-specific targets.
- Learn how GMP-compliant NGS platforms integrate into existing viral safety strategies.
- Examine real-world considerations for implementing advanced genomic testing in biologics development and manufacturing.
- Gain insights into risk mitigation approaches aligned with evolving regulatory and industry expectations.
About the speaker
Christine has worked at Minaris since 2007, starting her career in the Viral Clearance Group where she developed and validated viral qPCR assays.
In 2012, she joined the Analytical Sciences group where she contributed to the development of AgentSCREEN™ assays to detect adventitious viruses using Next Generation Sequencing, Cell Line Identity using Next Generation Sequencing, Replication Competent AAV (rcAAV) analysis by Long-Read sequencing, Integrated Vector Analysis,and Gene Copy titer assays for gene and cell therapy products using qPCR and ddPCR, and various other complex molecular biology methods.
Christine received a Ph.D. in Molecular Genetics from The State University of New York at Stony Brook.